

Natalie Staplin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9327593/publications.pdf>

Version: 2024-02-01

35
papers

11,957
citations

361045

20
h-index

377514

34
g-index

44
all docs

44
docs citations

44
times ranked

24211
citing authors

#	ARTICLE	IF	CITATIONS
1	Dexamethasone in Hospitalized Patients with Covid-19. <i>New England Journal of Medicine</i> , 2021, 384, 693-704.	13.9	8,063
2	Conventional and Genetic Evidence on the Association between Adiposity and CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 127-137.	3.0	39
3	Tocilizumab in COVID-19 therapy: who benefits, and how? "Authors' reply. <i>Lancet, The</i> , 2021, 398, 300.	6.3	3
4	Cardiac, renal, and metabolic effects of sodium-glucose co-transporter 2 inhibitors: a position paper from the European Society of Cardiology ad hoc task force on sodium-glucose co-transporter 2 inhibitors. <i>European Journal of Heart Failure</i> , 2021, 23, 1260-1275.	2.9	36
5	Association of Kidney Function With NMR-Quantified Lipids, Lipoproteins, and Metabolic Measures in Mexican Adults. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 2828-2839.	1.8	10
6	Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 499.	3.8	498
7	Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials. <i>EClinicalMedicine</i> , 2021, 41, 101163.	3.2	33
8	UMOD-ulating CKD risk: untangling the relationship between urinary uromodulin, blood pressure, and kidney disease. <i>Kidney International</i> , 2021, 100, 1168-1170.	2.6	3
9	Comparison of the Accuracy and Completeness of Records of Serious Vascular Events in Routinely Collected Data vs Clinical Trial-Adjudicated Direct Follow-up Data in the UK. <i>JAMA Network Open</i> , 2021, 4, e2139748.	2.8	15
10	Kidney disease trials for the 21st century: innovations in design and conduct. <i>Nature Reviews Nephrology</i> , 2020, 16, 173-185.	4.1	14
11	Apolipoprotein B, Triglyceride-Rich Lipoproteins, and Risk of Cardiovascular Events in Persons with CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 47-60.	2.2	41
12	Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. <i>New England Journal of Medicine</i> , 2020, 383, 2030-2040.	13.9	1,013
13	Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. <i>Lancet, The</i> , 2020, 396, 1345-1352.	6.3	569
14	Cross-sectional associations between central and general adiposity with albuminuria: observations from 400,000 people in UK Biobank. <i>International Journal of Obesity</i> , 2020, 44, 2256-2266.	1.6	9
15	Blood pressure and kidney disease: chicken or egg (or both)? <i>Kidney International</i> , 2020, 98, 547-549.	2.6	4
16	Mixed-effects models for slope-based endpoints in clinical trials of chronic kidney disease. <i>Statistics in Medicine</i> , 2019, 38, 4218-4239.	0.8	32
17	Prognostic utility of estimated albumin excretion rate in chronic kidney disease: results from the Study of Heart and Renal Protection. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, gfw396.	0.4	6
18	Declining comorbidity-adjusted mortality rates in English patients receiving maintenance renal replacement therapy. <i>Kidney International</i> , 2018, 93, 1165-1174.	2.6	21

#	ARTICLE	IF	CITATIONS
19	Impact of CKD on Household Income. <i>Kidney International Reports</i> , 2018, 3, 610-618.	0.4	25
20	Confounding is not the only bias influencing associations of adiposity with cardiovascular disease. <i>European Heart Journal</i> , 2018, 39, 1521-1522.	1.0	3
21	Campath, calcineurin inhibitor reduction, and chronic allograft nephropathy (the 3C Study) – results of a randomized controlled clinical trial. <i>American Journal of Transplantation</i> , 2018, 18, 1424-1434.	2.6	18
22	Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation. <i>Kidney International</i> , 2018, 93, 1000-1007.	2.6	32
23	The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study. <i>CKJ: Clinical Kidney Journal</i> , 2018, 11, 749-761.	1.4	196
24	Effects of Sacubitril/Valsartan Versus Irbesartan in Patients With Chronic Kidney Disease. <i>Circulation</i> , 2018, 138, 1505-1514.	1.6	145
25	Biliary Tract and Liver Complications in Polycystic Kidney Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 2738-2748.	3.0	19
26	Evidence for Reverse Causality in the Association Between Blood Pressure and Cardiovascular Risk in Patients With Chronic Kidney Disease. <i>Hypertension</i> , 2017, 69, 314-322.	1.3	30
27	Use of Causal Diagrams to Inform the Design and Interpretation of Observational Studies: An Example from the Study of Heart and Renal Protection (SHARP). <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 546-552.	2.2	41
28	Chronic kidney disease and the risk of cancer: an individual patient data meta-analysis of 32,057 participants from six prospective studies. <i>BMC Cancer</i> , 2016, 16, 488.	1.1	78
29	Effect of Processing Delay and Storage Conditions on Urine Albumin-to-Creatinine Ratio. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 1794-1801.	2.2	22
30	Smoking and Adverse Outcomes in Patients With CKD: The Study of Heart and Renal Protection (SHARP). <i>American Journal of Kidney Diseases</i> , 2016, 68, 371-380.	2.1	57
31	Impact of Educational Attainment on Health Outcomes in Moderate to Severe CKD. <i>American Journal of Kidney Diseases</i> , 2016, 67, 31-39.	2.1	42
32	Use of gel-based separator tubes to stabilise phosphate in mailed blood samples. <i>Clinica Chimica Acta</i> , 2015, 439, 112-114.	0.5	0
33	Evidence for the Prevention and Treatment of Stroke in Dialysis Patients. <i>Seminars in Dialysis</i> , 2015, 28, 35-47.	0.7	49
34	Evaluating the Contribution of the Cause of Kidney Disease to Prognosis in CKD: Results From the Study of Heart and Renal Protection (SHARP). <i>American Journal of Kidney Diseases</i> , 2014, 64, 40-48.	2.1	55
35	The Effect of Lowering LDL Cholesterol on Vascular Access Patency. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014, 9, 914-919.	2.2	19